Contents
Clinical research in Montana specializes in the coordination and management of Phase 1 to Phase 4 trials. Trained professionals combine years of experience and data to provide new treatments, drugs, and devices that can boost clinical practice.
Volunteers such as yourself are always welcome. With your help, experts can shape the very future of disease treatment. We can introduce you to clinical trials in your local area.
Clinical Trials For Disease Areas in Montana
Montana is one of the most rural areas in the United States. About 43.6% of its population lives in rural regions. Compared to regions with bigger cities, Montana doesn’t have a broad range of clinical research trials. But, those that are available provide access to quality care and use the latest technology.
Since 2004, roughly 1,200 clinical trials have been done in Montana. Many of the state’s trials focus on environmental health. Others try to address the unique challenges of rural health disparities and access to healthcare in remote areas.
For example, the Montana State Univerisity is actively engaged in the study of virology, microbiology, immunology, and molecular biology. Each sector has something unique to offer for medical advancements.
Want to participate in cutting-edge medical research? Browse our list of available trials in your local area.
Fabry Disease Registry & Pregnancy Sub-registry
Recruiting
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The primary objectives of the Registry are:
* To enhance the understanding of the variability, progression, and natural history of F... Read More
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The primary objectives of the Registry are:
* To enhance the understanding of the variability, progression, and natural history of Fabry disease, including heterozygous females with the disease;
* To assist the Fabry medical community with the development of recommendations for monitoring patients and reports on patient outcomes to help optimize patient care;
* To characterize and describe the Fabry population as a whole;
* To evaluate the long-term safety and effectiveness of Fabrazyme®
Fabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Fabry Registry, regardless of whether she is receiving disease-specific therapy (such as enzyme replacement therapy with agalsidase beta) and irrespective of the commercial product with which she may be treated. Data from the Sub-registry are also used to fulfill various global regulatory requirements, to support product development/reimbursement, and for other research and non-research-related purposes. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician. If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
08/07/2025
Locations: Shodair Children's Hospital- Site Number : 840090, Helena, Montana
Shodair Children's Hospital- Site Number : 840090, Helena, Montana
Conditions: Fabry Disease
Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens
Recruiting
Human phagocytic cells such as polymorphonuclear leukocytes (PMNs) are readily mobilized to sites of infection and ingest microorganisms by a process known as phagocytosis. The combined effects of reactive oxygen species (ROS) and proteolytic peptides and enzymes released into forming bacterial phagosomes kill most ingested bacteria. However, many human bacterial pathogens have devised means to subvert normal phagocyte responses and the innate immune response and cause severe disease.
The overa... Read More
Human phagocytic cells such as polymorphonuclear leukocytes (PMNs) are readily mobilized to sites of infection and ingest microorganisms by a process known as phagocytosis. The combined effects of reactive oxygen species (ROS) and proteolytic peptides and enzymes released into forming bacterial phagosomes kill most ingested bacteria. However, many human bacterial pathogens have devised means to subvert normal phagocyte responses and the innate immune response and cause severe disease.
The overall objective of this study is to elucidate specific features of pathogen-phagocyte interactions that underlie evasion of the innate immune response or contribute to the pathophysiology of disease or inflammatory disorders. Therefore, specific projects will:
1. Identify and characterize specific mechanisms used by pathogenic microorganisms to evade or subvert normal phagocyte responses and therefore cause disease.
2. Investigate phagocyte response mechanisms to specific pathogenic microorganisms.
3. Identify specific bacterial structures and/or (gene) products that dictate differences in phagocyte responses among a range of pathogens so that generalized statements can be made about the pathophysiology of disease states.
The studies will be performed using multiple techniques including state-of-the-art equipment for genomics and proteomics strategies to identify target bacterial genes/proteins of interest or those up-regulated in phagocytes. Phagocyte-pathogen interactions will be examined using fluorescence-based real-time assays and video microscopy, confocal and electron microscopy in combination with enzymatic assays for ROS production, routine biochemistry, immunology and cell biology.
Implementing these studies will require isolation of phagocytic leukocytes from venous blood of healthy human volunteers. The study population will be all-inclusive except in certain instances where individuals possess genetic defects that impair phagocyte function (e.g., myeloperoxidase-deficiency) or have altered phagocyte function due to outside influences such as recent bacterial or viral infection.
The proposed studies will likely provide new information pertinent to understanding host cell-pathogen interactions and the pathophysiology of inflammatory conditions. Read Less
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/22/2025
Locations: NIAID, Rocky Mountain Laboratories, Hamilton, Montana
NIAID, Rocky Mountain Laboratories, Hamilton, Montana
Conditions: Host Defense Mechanisms
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Local Institute, Missoula, Montana +1 locations
Local Institute, Missoula, Montana
Local Institute, Missoula, Montana
Conditions: Multiple Myeloma
Integrated Cancer Repository for Cancer Research
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies. Read Less
Gender:
ALL
Ages:
Between 19 years and 110 years
Trial Updated:
06/04/2025
Locations: Bozeman Health Deaconess Hospital, Bozeman, Montana +1 locations
Bozeman Health Deaconess Hospital, Bozeman, Montana
Logan Health, Kalispell, Montana
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control, Gastrointestinal Stromal Tumors, Central Nervous System Tumor, Central Nervous System Cancer
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Community Hospital of Anaconda, Anaconda, Montana +11 locations
Community Hospital of Anaconda, Anaconda, Montana
Billings Clinic Cancer Center, Billings, Montana
Saint Vincent Healthcare, Billings, Montana
Saint Vincent Frontier Cancer Center, Billings, Montana
Bozeman Deaconess Hospital, Bozeman, Montana
Saint James Community Hospital and Cancer Treatment Center, Butte, Montana
Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana
Great Falls Clinic, Great Falls, Montana
Saint Peter's Community Hospital, Helena, Montana
Kalispell Regional Medical Center, Kalispell, Montana
Saint Patrick Hospital - Community Hospital, Missoula, Montana
Community Medical Hospital, Missoula, Montana
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
Recruiting
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the c... Read More
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2025
Locations: Community Hospital of Anaconda, Anaconda, Montana +7 locations
Community Hospital of Anaconda, Anaconda, Montana
Billings Clinic Cancer Center, Billings, Montana
Bozeman Health Deaconess Hospital, Bozeman, Montana
Saint James Community Hospital and Cancer Treatment Center, Butte, Montana
Benefis Sletten Cancer Institute, Great Falls, Montana
Hi-Line Sletten Cancer Center, Havre, Montana
Saint Peter's Community Hospital, Helena, Montana
Logan Health Medical Center, Kalispell, Montana
Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Recruiting
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Billings Clinic Cancer Center, Billings, Montana +9 locations
Billings Clinic Cancer Center, Billings, Montana
Saint Vincent Healthcare, Billings, Montana
Bozeman Health Deaconess Hospital, Bozeman, Montana
Saint James Community Hospital and Cancer Treatment Center, Butte, Montana
Benefis Sletten Cancer Institute, Great Falls, Montana
Hi-Line Sletten Cancer Center, Havre, Montana
Saint Peter's Community Hospital, Helena, Montana
Logan Health Medical Center, Kalispell, Montana
Saint Patrick Hospital - Community Hospital, Missoula, Montana
Community Medical Center, Missoula, Montana
Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Creatine for Depressed Male and Female Methamphetamine Users
Recruiting
* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users
* Assess creatine's effect on methamphetamine use
* Assess the safety of creatine in male methamphetamine users with depression
* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users
* Assess creatine's effect on methamphetamine use
* Assess the safety of creatine in male methamphetamine users with depression Read Less
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
12/10/2015
Locations: Montana State University College of Nursing (Missoula campus), Missoula, Montana
Montana State University College of Nursing (Missoula campus), Missoula, Montana
Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin
Recruiting
This protocol describes a randomized, open-label study to evaluate the safety and tolerability of single-dose intravenous (IV) oritavancin diphosphate (oritavancin) versus standard of care (SoC) antibiotics for the treatment of pediatric subjects with acute bacterial skin and skin structure infections (ABSSSIs).
This study involves two oritavancin products, ORBACTIV® and KIMYRSATM. Oritavancin is the active drug substance in both ORBACTIV and KIMYRSA. This study protocol distinguishes the diffe... Read More
This protocol describes a randomized, open-label study to evaluate the safety and tolerability of single-dose intravenous (IV) oritavancin diphosphate (oritavancin) versus standard of care (SoC) antibiotics for the treatment of pediatric subjects with acute bacterial skin and skin structure infections (ABSSSIs).
This study involves two oritavancin products, ORBACTIV® and KIMYRSATM. Oritavancin is the active drug substance in both ORBACTIV and KIMYRSA. This study protocol distinguishes the differences between ORBACTIV and KIMYRSA by providing product-specific data, and information and guidance for Investigators. "Oritavancin" is used to describe drug product data, and information and guidance that is not specific to ORBACTIV or KIMYRSA (i.e., applies to both).
The study involves pharmacokinetic (PK) sampling and will evaluate clinical outcome assessments. The study was designed to capture adequate data while minimizing the impact to subjects and their caregivers. Read Less
Gender:
ALL
Ages:
Between 3 months and 17 years
Trial Updated:
07/09/2025
Locations: Multiprofile Hospital for Active Treatment- Sveti Nikolay Chudotvoretz - LOM EOOD, Lom, Montana
Multiprofile Hospital for Active Treatment- Sveti Nikolay Chudotvoretz - LOM EOOD, Lom, Montana
Conditions: Acute Bacterial Skin and Skin Structure Infection
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
Recruiting
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months.
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months. Read Less
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/13/2025
Locations: Mercury Street Medical Group, PLLC, Butte, Montana +1 locations
Mercury Street Medical Group, PLLC, Butte, Montana
Diagnostic Consultative Center - 1 Lom EOOD, Lom, Montana
Conditions: COVID-19 SARS-CoV-2 Infection
Paid Clinical Trials in Montana
Every treatment, medical device, and therapy is carefully tested before it becomes available to the public. Paid clinical trials provide patients with the perfect opportunity to earn something in exchange for participating in trials.
MT paid clinical trials provide different forms of compensation. You can get paid or receive non-monetary benefits. Like free medical care, or compensation for traveling and accommodation expenses.
Clinical Trials For Health Volunteers in Montana
Research teams in Montana need you to make a lasting impact. By taking part in a clinical trial, you are not just a volunteer, you are a pioneer who can help take healthcare to a completely different level.
Take a look at the trial list below to find the one that suits you best.
Integrated Cancer Repository for Cancer Research
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies. Read Less
Gender:
ALL
Ages:
Between 19 years and 110 years
Trial Updated:
06/04/2025
Locations: Bozeman Health Deaconess Hospital, Bozeman, Montana +1 locations
Bozeman Health Deaconess Hospital, Bozeman, Montana
Logan Health, Kalispell, Montana
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control, Gastrointestinal Stromal Tumors, Central Nervous System Tumor, Central Nervous System Cancer
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Recruiting
Background:
Infections in the lower respiratory tract (lungs) are the leading cause of death from infectious disease worldwide. This was true even before the COVID-19 pandemic. Respiratory viruses are still a major health threat. Many of these viruses infect people by penetrating the thin skin that lines the nose. These viruses can also spread easily to other people when they multiply in the tissues that line the nose. Researchers want to learn more about what these viruses do inside the nose,... Read More
Background:
Infections in the lower respiratory tract (lungs) are the leading cause of death from infectious disease worldwide. This was true even before the COVID-19 pandemic. Respiratory viruses are still a major health threat. Many of these viruses infect people by penetrating the thin skin that lines the nose. These viruses can also spread easily to other people when they multiply in the tissues that line the nose. Researchers want to learn more about what these viruses do inside the nose, how they get from the nose to the lungs, and how they spread from person to person.
Objective:
To collect cell samples from inside the noses of healthy people. These cells will be stored for use in future research on respiratory diseases.
Eligibility:
Healthy volunteers aged 18 years and older.
Design:
Most participants will have 1 visit on 1 day. They will be asked questions. Those who have a runny nose, coughing, congestion, or fever will be asked to wait up to 21 days before participating.
Participants will be given a slender swab with small bristles at the end. They will rub the inside of their nose with the swab. A clinic staff member will be present to help, if needed.
Participants will provide their name, age, and sex. This information will be encoded so that only certain researchers will know the participants identities.
Participants will not be contacted again.... Read Less
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/09/2025
Locations: Rocky Mountain Laboratories, Hamilton, Montana
Rocky Mountain Laboratories, Hamilton, Montana
Conditions: Healthy
Medical Discoveries and Innovation in Montana
Many medical discoveries and achievements come from Montana research institutions. They reflect the expertise of medical specialists over the years. These include:
- Advancements in Rural Healthcare Delivery: The Montana AHEC Program has been critical in developing new and improved approaches to deliver quality care to underserved and rural areas. Their initiatives improved access to healthcare services across all MT communities.
- Traumatic Brain Injury Research: Clinical studies in the area made notable contributions to the treatment of traumatic brain injuries. Each trial has helped improve interventions and protocols for patients with severe brain injuries.
- Environmental Health Research: The state of Montana has the latest biomedical research equipment. The University of Montana has done numerous studies about the impact of environmental factors on overall health. The data collected can help improve available treatments for various diseases.
Why Montana Is A Great Place For Clinical Research
Montana clinical research can benefit from volunteers of different ethnic and racial backgrounds. Here, 85.5% of its population is White, 6% is American Indian, 4.3% is Hispanic, 2.6% is Multiracial, 1% is Asian, and 0.6% is Black.